BiotechTube

Vismodegib

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Basal Cell Carcinoma

Conditions

Basal Cell Carcinoma, Radiotherapy; Complications

Trial Timeline

Jun 20, 2023 → Jun 20, 2029

NCT ID
NCT05561634

About Vismodegib

Vismodegib is a phase 2 stage product being developed by Sun Pharmaceutical for Basal Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05561634. Target conditions include Basal Cell Carcinoma, Radiotherapy; Complications.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05561634Phase 2Recruiting

Competing Products

20 competing products in Basal Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
Part 1: VP-315 3 Day Dosing/Week + Part 2: VP-315 3 Day Dosing/Week - Loading Dose + Part 2: VP-315 3 Day Dosing/Week - No Loading Dose + Part 2: VP-315 2 Day Dosing/Week - Split Dose + Part 2: VP-315 3 Day Dosing/Week - Split DoseVerrica PharmaceuticalsPhase 2
44
sonidegibSun PharmaceuticalPre-clinical
23
Sonidegib Phosphate CapsulesSun PharmaceuticalApproved
85
Cemiplimab Injection [Libtayo]Sun PharmaceuticalPhase 2
52
Vismodegib + SonidegibSun PharmaceuticalPre-clinical
23
Natural Killer Cell Therapy + Universal Donor Expanded TGF-beta-imprinted NK CellsJohnson & JohnsonPhase 1
33
ABBV-8E12AbbViePre-clinical
23
Pembrolizumab + VismodegibMerckPhase 1/2
41
LDE225B + VehicleNovartisPhase 2/3
65
verteporfin PDTNovartisPhase 3
77
Vehicle + LDE225 0.25% + LDE225 0.75%NovartisPhase 2
52
LDE225NovartisPhase 2
52
LDE225 + PlaceboNovartisPhase 2
52
Buparlisib + SonidegibNovartisPhase 2
52
LDE225NovartisPre-clinical
23
LDE225 0.75% + VehicleNovartisPhase 2
52
VismodegibRochePre-clinical
23
ERIVEDGERochePhase 2
52
Placebo + VismodegibRochePhase 2
52
vismodegibRochePhase 2
52

Other Products from Sun Pharmaceutical

Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85